Safety of Bisphosphonates To Be Reviewed By FDA Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will meet Sept. 9 to review the safety of long-term use of bisphosphonates in treating osteoporosis.